| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8792513 | Journal of American Association for Pediatric Ophthalmology and Strabismus | 2016 | 12 Pages |
Abstract
All eyes treated with 0.25mg/0.01ml intravitreal bevacizumab showed complete regression, with no recurrence of plus disease or neovascularization. No safety issues were attributable to bevacizumab during the study period.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Alireza MD, Mohammad Reza MD, Ramak MD,